Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01343667 · ClinicalTrials.gov registry record · NA
GORE Flow Reversal System and GORE Embolic Filter Extension Study
A NA study, sponsored by W.L.Gore & Associates.
- Completed
- Registry status
- NA
- Development phase
- 1,397
- Enrollment target
NCT01343667 is a NA study that has completed, run by W.L.Gore & Associates. The registered enrollment target is 1,397 participants.
The verdict
NCT01343667, a NA study, has completed, sponsored by W.L.Gore & Associates.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,397 participants
- Enrollment target
Study Summary
The objective of this study is to provide an ongoing evaluation of clinical outcomes associated with the GORE Flow Reversal System and the GORE Embolic Filter when used for embolic protection during carotid artery stenting.
Interventions
- DEVICE Gore Flow Reversal System
- DEVICE Gore Embolic Filter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,397 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01343667
The ClinicalTrials.gov registry entry for NCT01343667 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,397 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gore Flow Reversal System is the first listed.
NCT01343667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01343667 about?
NCT01343667 is a clinical study titled "GORE Flow Reversal System and GORE Embolic Filter Extension Study". The objective of this study is to provide an ongoing evaluation of clinical outcomes associated with the GORE Flow Reversal System and the GORE Embolic Filter when used for embolic protection during carotid artery stenting.
What is the current status of trial NCT01343667?
This trial is currently completed. It is a NA study. The enrollment target is 1,397 participants. The study started on 2011-04. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01343667?
The interventions under investigation include: Gore Flow Reversal System (DEVICE), Gore Embolic Filter (DEVICE).
Who is sponsoring clinical trial NCT01343667?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.